Claudin 4 (CLDN4) Rabbit Polyclonal Antibody

CAT#: TA321325S

Anti-CLDN4 Rabbit Polyclonal Antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 800.00

CNY 1,280.00


货期*
2周

规格
    • 25 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human claudin 4 (CLDN4), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Transient overexpression lysate of claudin 4 (CLDN4)
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Applications IHC, WB
Recommend Dilution WB: 1000-3000
WB positive control: HT-29 cells
IHC: 25-100
Positive control: Human breast cancer
Predicted cell location: Cytoplasm, Cell membrane
Reactivity Human, Mouse
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide corresponding to a region derived from 193-209 amino acids of Human claudin 4
Formulation PBS pH7.3, 0.05% NaN3, 50% glycerol
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 22 kDa
Gene Name claudin 4
Background Claudin 4; also known as CLDN4; is a protein which in humans is encoded by the CLDN4 gene. It belongs to the group of claudins. This gene encodes an integral membrane protein; which belongs to the claudin family. The protein is a component of tight junction strands and may play a role in internal organ development and function during pre- and postnatal life. This gene is deleted in Williams-Beuren syndrome; a neurodevelopmental disorder affecting multiple systems.
Synonyms CPE-R; CPER; CPETR; CPETR1; hCPE-R; WBSCR8
Reference Data
Protein Families Druggable Genome, Transmembrane
Protein Pathways Cell adhesion molecules (CAMs), Leukocyte transendothelial migration, Tight junction
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...